Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Amortization of Deferred Charges (2023 - 2025)

Historic Amortization of Deferred Charges for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 3 years, with Q2 2025 value amounting to $6.8 million.

  • Lifecore Biomedical, Inc. \De\'s Amortization of Deferred Charges rose 1267.82% to $6.8 million in Q2 2025 from the same period last year, while for May 2025 it was $20.2 million, marking a year-over-year increase of 3111.64%. This contributed to the annual value of $20.2 million for FY2025, which is 3111.64% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Amortization of Deferred Charges amounted to $6.8 million in Q2 2025, which was up 1267.82% from $4.6 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Amortization of Deferred Charges' 5-year high stood at $6.8 million during Q2 2025, with a 5-year trough of $3.0 million in Q3 2023.
  • Its 3-year average for Amortization of Deferred Charges is $4.5 million, with a median of $4.4 million in 2024.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first soared by 5600.0% in 2024, then soared by 1267.82% in 2025.
  • Over the past 3 years, Lifecore Biomedical, Inc. \De\'s Amortization of Deferred Charges (Quarter) stood at $3.1 million in 2023, then skyrocketed by 31.02% to $4.1 million in 2024, then skyrocketed by 65.95% to $6.8 million in 2025.
  • Its Amortization of Deferred Charges was $6.8 million in Q2 2025, compared to $4.6 million in Q1 2025 and $4.1 million in Q4 2024.